相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J. Motzer et al.
EUROPEAN UROLOGY (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
Rabbia Siddiqi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal cell carcinoma (RCC): A systematic review and meta-analysis.
Tobias Engel Ayer Botrel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch et al.
DRUGS (2020)
Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients
Idir Ouzaid et al.
FRONTIERS IN SURGERY (2020)
Genomic profiling in renal cell carcinoma
Nazli Dizman et al.
NATURE REVIEWS NEPHROLOGY (2020)
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Elie Rassy et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma
Ciro Franzese et al.
JOURNAL OF UROLOGY (2019)
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
Axel Bex et al.
FUTURE ONCOLOGY (2019)
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Laurence Albiges et al.
EUROPEAN UROLOGY (2019)
Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study
Cedric Lebacle et al.
BJU INTERNATIONAL (2019)
Association between age and sex and mortality after adjuvant therapy for renal cancer
Ronac Mamtani et al.
CANCER (2019)
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Daniel J. George et al.
CLINICAL CANCER RESEARCH (2019)
Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies
Juan Chipollini et al.
THERAPEUTIC ADVANCES IN UROLOGY (2019)
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
Daniel J. George et al.
CLINICAL CANCER RESEARCH (2018)
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2018)
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Cora N. Sternberg et al.
CLINICAL CANCER RESEARCH (2018)
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun et al.
EUROPEAN UROLOGY (2018)
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
Robert J. Motzer et al.
EUROPEAN UROLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M. Gross-Goupil et al.
ANNALS OF ONCOLOGY (2018)
Evaluation of Disease-Free Survival as an Intermediate Metric of Overall Survival in Patients With Localized Renal Cell Carcinoma: A Trial-Level Meta-Analysis
Lauren C. Harshman et al.
CANCER (2018)
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
Chiara Ciccarese et al.
EUROPEAN JOURNAL OF CANCER (2017)
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B. Haas et al.
JAMA ONCOLOGY (2017)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies
Brian Rini et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Management of metastatic renal cell carcinoma mini - review
Anubha Bharthuarl et al.
JOURNAL OF KIDNEY CANCER AND VHL (2015)
ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
Samira A. Brooks et al.
EUROPEAN UROLOGY (2014)
PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Alexander W. MacFarlane et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeted therapies and the treatment of non-clear cell renal cell carcinoma
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery
Brian I. Rini et al.
JOURNAL OF UROLOGY (2012)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont et al.
LANCET ONCOLOGY (2012)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
Multi-institutional validation of a new renal cancer-specific survival nomogram
Pierre I. Karakiewicz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Advanced renal cell carcinoma - current and emerging management strategies
Bernard Escudier
DRUGS (2007)
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system
JS Lam et al.
JOURNAL OF UROLOGY (2005)
Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy:: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
J Atzpodien et al.
BRITISH JOURNAL OF CANCER (2005)
Multi-institutional validation of a symptom based classification for renal cell carcinoma
JJ Patard et al.
JOURNAL OF UROLOGY (2004)
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An International Multicenter Study
JJ Patard et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial
JI Clark et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III study of interferon Alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An eastern cooperative oncology group/intergroup trial
EM Messing et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials
BC Leibovich et al.
CANCER (2003)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
NK Janzen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score
I Frank et al.
JOURNAL OF UROLOGY (2002)
Improved prognostication of renal cell carcinoma using an integrated staging system
A Zisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Systemic therapy for renal cell carcinoma
RJ Motzer et al.
JOURNAL OF UROLOGY (2000)
分享论文
